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We have developed an animal model of degeneration of the nigrostriatal dopaminergic neurons, the neuronal system involved
in Parkinson’s disease (PD). The implication of neuroinﬂammation on this disease was originally established in 1988, when the
presence of activated microglia in the substantia nigra (SN) of parkinsonians was reported by McGeer et al. Neuroinﬂammation
could be involved in the progression of the disease or even has more direct implications. We injected 2μgo ft h ep o t e n t
proinﬂammatory compound lipopolysaccharide (LPS) in diﬀerent areas of the CNS, ﬁnding that SN displayed the highest
inﬂammatory response and that dopaminergic (body) neurons showed a special and speciﬁc sensitivity to this process with the
induction of selective dopaminergic degeneration. Neurodegeneration is induced by inﬂammation since it is prevented by anti-
inﬂammatory compounds. The special sensitivity of dopaminergic neurons seems to be related to the endogenous dopaminergic
content, since it is overcome by dopamine depletion. Compounds that activate microglia or induce inﬂammation have similar
eﬀects to LPS. This model suggest that inﬂammation is an important component of the degeneration of the nigrostriatal
dopaminergic system, probably also in PD. Anti-inﬂammatory treatments could be useful to prevent or slow down the rate of
dopaminergic degeneration in this disease.
1.Introduction
The pathological hallmark of Parkinson’s disease (PD), an
age-related neurodegenerative disorder, is the speciﬁc and
progressive degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) [1]. This results
in extrapiramidal motor dysfunction accompanied by pro-
gressive impairment of autonomy, mood, and cognitive
functions [1–3]. Although some genes have been identiﬁed
as responsible for rare familial early onset PD [4], its
etiology remains elusive and many distinct possibilities have
been pointed out for that. The eﬀects of exogenous agents,
infection, inﬂammatory response, and selective oxidative
stress in the SN have been suggested as the most probable
causesofthedopaminergicdegenerationintheSN[5].Many
exogenous compounds have been described to produce
degeneration of dopaminergic neurons in the nigrostri-
atal system, as 6-hydroxydopamine (6-OHDA), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and
m a n yo t h e rp e s t i c i d e s[ 6], which suggest an energetic
metabolism impairment as main cause of the disease. Other
possibilities were also proposed, as head trauma, encephali-
tis, reduced expression of trophic factors, alterations of
the ubiquitin-proteasome system and neuroinﬂammatory2 ISRN Neurology
mechanisms that are thought to collaborate in the progres-
sive demise of SNpc neurons [1, 3, 7–13].
The implication of neuroinﬂammation as a component
of the neurodegeneration progress of the disease was orig-
inally established in 1988 when the presence of activated
microglia in the SN of PD was reported (see [14]; for review
see [15, 16]). In that moment, the fact that many cases of
PD were accompanied with a general brain inﬂammation
along with the neurodegeneration was pointed out [14,
17, 18]. The dramatic proliferation of reactive amoeboid
macrophages and microglia seen in the SN of parkinsonian
brains, together with oxidative stress, was highly compatible
with the existence of an inﬂammatory process similar to that
previously described for Alzheimer’s disease (AD) [19]a n d
multiple sclerosis [20].
All these data allowed suggesting the implication of
inﬂammation in the neurodegeneration of nigrostriatal
dopaminergic neurons; however, its importance was not
clear. Is this process exclusively involved in the progress of
degenerationor could it have other implications? Is it able to
induce the neurodegeneration of dopaminergic neurons?
To address these questions, we took advantage of li-
popolysaccaride (LPS), a component of the Gram-negative
bacteria cell wall. LPS is a potent inducer of inﬂammation
and has diverse eﬀects on cells of the immune system [21].
It was described that the intracerebral injection of LPS
activated glial cells in vivo [22–26]; these microglial cells
could contribute to the neurotoxicity by secreting neurotox-
ins [27–32] including inﬂammatory cytokines, N-methyl-D-
aspartate (NMDA) receptor agonists, oxygen free radicals,
and nitric oxide (NO). Besides, in vitro studies [33]s h o w e d
that dopaminergic neurons were twice as sensitive to the
toxic eﬀects of LPS as tyrosine hydroxylase (TH) negative
neurons. All these data suggested that the injection of LPS
in diﬀerent areas of the brain could be a good experimental
model to ascertain the importance of inﬂammation in such
diﬀerent areas and neurons.
2.Nigral Dopaminergic Neurons
Degeneration(Loss)Producedby
the InﬂammatoryProcesses Inducedby
the IntranigralInjectionofLPS
We injected 2 μL of a solution containing 1mg of LPS/mL
and 1% Monastral blue inert tracer in phosphate-buﬀered
saline [34] in the left SN of female rats previously anes-
thetized. The results showed a signiﬁcant inﬂammation with
activation of microglia, a typical characteristic of brain
inﬂammation. This eﬀect was accompanied by the loss of
dopaminergic neurons (Figure 1)a n dt h ed e c r e a s eo ft h e
intracellular content of dopamine (DA) and its metabolites
in SN and striatum. These eﬀects suggested the loss of
dopaminergic neurons of SN along with its terminals in
striatum. This was corroborated by the loss of TH activity,
mainly in striatum. The highest loss was found 15 days
after the lesion and maintained during the 21 days of the
experiments. The average loss of the dopaminergic system
w a sa r o u n d3 5 % ;a tt h i sl e v e l ,r a t ss h o w e dn oo b v i o u s
m o t o rd i s t u r b a n c e s .A n o t h e ri n t e r e s t i n gr e s u l tc a m ef r o m
serotonin (5-HT); although 5-HT levels in the SN reached
a minimum 15 days after the lesion, they recovered to the
initial levelsby day 21. These results obviously suggested that
the degenerative process induced by inﬂammation (LPS) in
the SN was speciﬁc for dopaminergic neurons and allowed
us to suggest that the injection of a single dose of LPS
within the SN could be an interesting model for studying the
selective eﬀects of inﬂammatory reactions on dopaminergic
system, and potentially for studying PD. Moreover, taking
i n t oa c c o u n tt h a tA n d e r s s o ne ta l .[ 23] had shown a loss of
pyramidal cells in the CA1 ﬁeld in mice following an acute
intrahippocampal infusion of 2μgo fL P S ,w eu s e dt h i sd o s e
to study the speciﬁcity of the LPS eﬀectin diﬀerentareas and
neuronsofthebrain.Speciﬁcitywouldobviouslyincreasethe
importance of the eﬀect.
3.The SNIsthe Most SensitiveArea ofthe
Brain to theInﬂammationInducedby the
InjectionofLPS,Which ProducedaSelective
Degenerationof Dopaminergic Neurons
We injected 2 μL of the LPS solution described before into
four diﬀerent locations: the left SN, the medial forebrain
bundle (MFB), the striatum, and the dorsal raphe nucleus
(DR) [35]. LPS induced a strong macrophage/microglial
reaction in SN, with a characteristic clustering of ma-
crophage cells around blood vessels. These macrophage
cells contained blue particles inside (from Monastral blue),
indicating phagocytic activity. Fifteen days after injection,
the number of lipid-laden cells began to decrease gradually
and 1 year after injection most of the OX-42-positive
cells showed ramiﬁed morphology. The SN was far more
sensitive than the striatum and the other areas studied to the
inﬂammatory stimulus. Moreover, only the dopaminergic
neurons of the SN were aﬀected, with no detectable damage
to either the GABAergic or the serotoninergic neurons. The
damage to the DA neurons in the SN was permanent, as
observed 1 year after injection. Moreover, the injection of
LPS into MFB did not produce any signiﬁcant eﬀect on the
inﬂammation process, nor neuronal degeneration. Similar
results were found when injections were made within the
striatum or the DR. Therefore, these results seem to support
that the injection of a single dose of LPS within the SN
produced a selective eﬀect on the dopaminergic neurons.
Moreover, this work pointed out that inﬂammation was
able to induce the degeneration of nigral dopaminergic
neurons; the induction of inﬂammatory processes could be
involved in the degeneration of dopaminergic neurons after
injury (as boxing) or infection; it could also be involved in
the progression of neuronal degeneration induced by other
causes. Kim et al. [36] published the same conclusions. They
also studied the eﬀect of LPS injection within hippocampus
and found no signiﬁcant induction of inﬂammation or
neuronal degeneration. Neurotoxicity after intraparenchy-
mal injection of LPS has also been reported by other authors
[37, 38].ISRN Neurology 3
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Figure 1: Eﬀect of LPS on glial cells and dopaminergic neurons. (a) Injection of vehicle within the SN; (b) injection of LPS. OX-6 is a
commercial antibody directed against a monomorphic determinant of the rat major histocompatibility complex (MHC) class II antigens,
expressed byactivated microgliabut notfortherestingcells. LPSincreasesOX-6 immunoreactivityaroundtheinjection track,ﬁllingthearea
of activated microglia characterized by its round morphology. On the contrary, there is an area lacking GFAP immunoreactivity, a marker
of astroglia, around the injection site of LPS. As hallmark of this model, LPS induces the loss of dopaminergic (TH positive) neurons in the
SN. Scalebar: 500μm. (c) Represents the averagevalues ofsomeparameters inthe SN(as percentage ofcontrols) after the singleinjection of
2μg of LPS: DA/TH/DAT, dopamine content, neurons expressing tyrosine hydroxylase, and dopamine transporter; OX-42/OX-6, density of
activated microglial cells; amounts ofthe proinﬂammatorycytokines TNF-α and IL-1β, the adhesion molecule ICAM-1, the inducible nitric
oxide synthase (iNOS), and the heat shock protein (HSP)-70; the phosphorylated (active) forms of the MAP kinases p38 (associated with
promotion of apoptosis) and Akt (cell surviving signal). Alterations on the expression of GFAP and the endothelial barrier antigen (EBA),
as area lacking expression (in mm2), are also shown.4 ISRN Neurology
4. Protective EffectProducedby the Treatment
withAnti-Inﬂammatory CompoundsonThis
NeurodegenerativeModel
O b v i o u s l y ,t h ep o s s i b l ep r o t e c t i v ee ﬀect of an anti-inﬂam-
matory compound would support this model along with
the importance of the inﬂammatory response in the LPS-
induced degeneration of the nigral dopaminergic neurons.
Inﬂammation is an attractive pharmacological target since
it progresses over several days after injury and because
intervention with anti-inﬂammatory agents may not result
in intolerable side-eﬀects [39].
4.1.Dexamethasone. Thus,weuseddexamethasone,apotent
anti-inﬂammatory drug. It was known that glucocorticoids
were potent anti-inﬂammatory drugs that have long been
used in clinical neurology for the treatment of brain inﬂam-
mation [40, 41] and spinal cord injury [42]. They are potent
inhibitors of the IFN-induced activation of microglia and
macrophages in vitro [43] and downregulates the expression
of the major histocompatibility complex (MHC) class II
molecules on macrophages, both in vivo and in vitro [44].
Dexamethasone prevents the induction of cyclo-oxygenase
(COX)-2 mRNA and prostaglandins in the lumbar spinal
cord following intraplantar injection of Freund’s complete
adjuvant, in parallel with inhibition of edema [45]. More-
over, dexamethasone down-regulates the expression ofMHC
class II on rat microglia [43, 46] and reversibly inhibits the
microglialproliferationinvitro [47]inducedbyaxotomyand
IFN-γ.
When animals were treated with dexamethasone [48], we
found a signiﬁcant protection against the damage caused by
the intranigral injection of LPS. The treatment with dexam-
ethasone interferes with many of the features characterizing
proinﬂammatory glial activation, proliferation and also the
upregulated expression of the MHC class II produced by
LPS. We found that dexamethasone inhibited not only the
number of OX-42-positive cells but also the number of
microglia/macrophages expressing MHC class II antigens as
revealed by staining with OX-6. These observations were in
agreement with previous works reporting that glucocorti-
coids downregulate MHC class II [43, 44, 46].
Dexamethasone treatment was also able to prevent the
loss of DA and its metabolites in SN and striatum. Similarly,
it also prevented the loss of TH (measured by its activity and
by TH immunostaining) in SN and striatum. These results
conﬁrmed that inﬂammatory response was implicated in
LPS-induced neurodegeneration and open the possibility to
use anti-inﬂammatory drugs to slow down the progress of
the disease.
4.2. Minocycline. We have used other anti-inﬂammatory
compounds; minocycline is a semisynthetic tetracycline
derivative that is able to cross the BBB, reaching the cere-
brospinal ﬂuid [49]. Moreover, this new antibiotic exerts
anti-inﬂammatory eﬀects that are completely separated and
distinct from its antimicrobial origin [50–52]; its use in
neurodegenerative diseases has been suggested. Minocycline
has been shown to protect hippocampal neurons against
globalischemia [53]andtoreducecorticalinfarction volume
in a rat model of focal brain ischemia [54]. It is also a
very eﬃcient neuroprotective agent in animal models of
traumatic brain injury [55], multiple sclerosis [56], Hunt-
ington’s disease [57], and amyotrophic lateral sclerosis [58].
Moreover, other studies had also demonstrated a neuropro-
tective eﬀectofminocycline overthe dopaminergicsystemin
response to either MPTP [59, 60]o r6 - O H D A[ 61].
Whenwe evaluatedthepotential neuroprotectiveactivity
of minocycline in our animal model of Parkinson’s disease
induced by the intranigral injection of LPS [62], we found it
was very eﬀective preventing diﬀerent inﬂammatory features
along with the loss of nigral dopaminergic neurons. Minocy-
cline treatment highly prevented the activation of reactive
microglia as visualized by OX-42 and OX-6 immunohisto-
chemistry, as well as the induction of interleukin (IL)-1α
and tumor necrosis factor (TNF)-α mRNAs. Moreover,
minocycline treatment also partially prevented the loss of
dopaminergic neurons (12% against 50%) produced by LPS.
4.3. Simvastatin. At this time, some experimental and clini-
cal evidence indicated that statins—extensively used in med-
ical practice as eﬀective lipid-lowering agents through the
inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase—
had other cholesterol independent eﬀects, as improving
endothelial function, decreasing oxidative stress, inhibit-
ing the thrombogenic response in the vascular wall,
immunomodulatoryand,anti-inﬂammatory properties[63–
67]. Thus, we investigated the inﬂuence of simvastatin on
the degenerative process of the dopaminergic neurons in our
animal model of Parkinson’s disease [68, 69]. In these works,
we found that simvastatin treatment prevented the inﬂam-
matory process induced by LPS. Simvastatin prevented
the bulk microglial activation found after LPS injection,
reducing the number of microglia/macrophages expressing
MHC class II antigens (40% of LPS group) as revealed by
immunostaining with OX-6; it also inhibited the activation
of IL-1β,T N F - α, and inducible nitric oxide synthase (iNOS)
produced by LPS. These eﬀects could be, at least, one of
the causes of the prevention of dopaminergic neuronal loss
induced by LPS produced by the simvastatin treatment.
However, simvastatin showed another important eﬀect that
could help to the survival of dopaminergic neurons: sim-
vastatin produced the activation of the neurotrophic factor
BDNF, along with the prevention of the oxidative damage
to proteins, conditions in which BDNF has an important
protective eﬀect.Moreover, it also preventsthe main changes
produced by LPS on diﬀerent mitogen-activated protein
kinases, featured as increases of P-c-Jun N-terminal protein
kinase, P-extracellular signal-regulated kinase, p-38, and P-
glycogen synthase kinase and the decrease of the promotion
of cell survival signals such as cAMP response element-
binding protein and Akt. Our results suggest that statins
coulddelay the progression ofdopaminergic degenerationin
disorders involving inﬂammatory processes.
Many other anti-inﬂammatory compounds have been
described to act as neuroprotectors in this and otherISRN Neurology 5
models of Parkinson’s disease. Nalaxone, an opiate receptor
antagonist, and its inactive isomer (+)-nalaxone, inhibited
boththeactivation of microglia andtheloss ofdopaminergic
neurons induced by LPS in the SN [37, 38]. This eﬀect was
improved when nalaxone was combined with indomethacin
[70]. Triptolide, another anti-inﬂammatory compound, also
prevents the dopaminergic degeneration induced by LPS
intranigral injection [71]. A similar eﬀect was also produced
by silymarin [72] and catalpol [73], other anti-inﬂammatory
compounds.
5.Why Does the SNHavea Special
Sensitivityto the InﬂammationInducedby
theInjectionofLPS?
As described above, our results showed that the inﬂam-
matory reaction was stronger in SN than in striatum and
other areas studied [34–36]. This was also clear in the
characteristic disappearance of the GFAP immunoreactivity
at the LPS injection site. We suggested at that moment that
the diﬀerences could be due to speciﬁc structural diﬀerences
between the SN and other areas. Regarding this, it was
thought that SN had the highest concentration of microglia
in the brain [74] and consequently a high concentration
of the inﬂammation-related factors produced by these cells,
such as TNF-α and NO. This proposal is supported by
the fact that many anti-inﬂammatory compounds pro-
tect dopaminergic neurons. However, other authors have
reported more recently that in intact brain, the densities of
CD11b+ microgl´ ıa are similar in SNpc and cortex, although
LPS injection enhanced the number of CD11b+ cells in the
former but not in the latter [75].
Other possibilities have been pointed out, as the increase
in vascularization induced by inﬂammation in the SN, also
described in a MPTP model of PD that is accompanied by
theincreaseinthevascularendothelialgrowthfactor(VEGF)
[76]. One of the eﬀects of the change could be the increase
in the BBB permeability that could have some inﬂuence in
the sensitivity, since the intranigral injection of VEGF also
induce the degeneration of the dopaminergic system [77].
Another important consequence could be the inﬁltration
of peripheral monocytes/macrophages, which could act as
protector or neurotoxic [78]. These circumstances could
increase the sensitivity of SN to inﬂammation.
6.Why Are the Dopaminergic
Neuronsofthe SNEspeciallyAffected in
OurInﬂammationModel?
We had described that dopaminergicneuronswere especially
sensitive to inﬂammation, and this did not occur when LPS
was delivered within the MFB (dopaminergic axons) or the
striatum (dopaminergic terminals). The main suggestion
was that SN was highly vulnerable to oxidative damage [79–
82], taking into account its reduced antioxidative capability
along with its high content on iron and DA [83]. However,
this rationale did not accountfor the special sensitivity of the
DA neurons with respect to other non-DA neurons within
the SN, such as the GABAergic ones. Although unexplained,
this is very interesting for Parkinson’s disease, in which the
dopaminergic neurons are especially sensitive, probably not
only due to the inﬂammatory process.
Toanswerthisquestion,westudiedthepossibleinﬂuence
of DA. There was a general agreement on the toxic capa-
bility of DA, which generates redox metabolites including
semiquinone, quinone, zwitterionic 5,6-hydroxyindoles, and
possibly oxygen free radicals. Theoretically, this neurotoxic-
ity also accelerates autooxidation of the released DA, which
results in the generation of free radicals in vivo (Figure 2).
Enhanced DA autoxidation and oxygen free radicals may
initiate a cascade of oxidant stress, leading to injury and
loss of SNc neurons in Parkinson’s disease. This possibility
is supported by increased basal malonaldehyde formation
(lipidperoxidation)andironcontentinsurviving pigmented
SN neurons [80, 84, 85].
To test the involvement of DA in the degeneration
induced by LPS, we treated albino Wistar rats with dif-
ferent concentrations of α-methyl-p-tyrosine (α-MPT), an
inhibitor of TH activity that blocks synthesis of cytoplasmic
DA [86, 87]. Pretreatment with α-MPT reduces DA content
by 79% [88]. Results showed that α-MPT prevented, in a
dose-dependent manner, the inﬂammatory features induced
by LPS: activation of microglial cells (characterized by a
change of morphology from resting, ramiﬁed cells with thin
processes, to reactive microglial cells that eventually become
phagocytic), loss of the astroglial population accompanied
by the appearance of GFAP immunoreactive debris from
hypertrophic, degenerating astrocytes, loss of TH immunos-
taining, and expression ofmRNAforTH andDAtransporter
(DAT). These protective eﬀects resulted from inhibition of
TH and the consequent decrease in DA concentration, since
cotreatment with L-DOPA/benserazide, which bypasses TH
inhibition increasing the extracellular levels of DA in the
SN approximately fourfold with respect to basal levels [89],
avoided the protective eﬀects induced by inhibition of TH
produced by α- M P Ta n dr e s t o r e dt h ed e g e n e r a t i v ee ﬀects
induced by LPS on dopaminergic neurons as well as the
loss of astrocytes. All these results strongly supported the
implication of DA in the dopaminergic neurodegeneration
induced by LPS in the SN. Moreover, not only did DA
seem to be involved in dopaminergic degeneration of the
SN but it could also be responsible for the special sensitivity
of the SN to the inﬂammation induced by LPS. The SN
inﬂammatory response to LPS injection after TH inhibition
was similar to that described for other brain areas, where
LPS had little or no eﬀect on neuron degeneration or the
glial inﬂammatory process [35, 36]. However, the treatment
with LPS + α-MPT + L-DOPA/benserazide did not produce
activation of microglial cells, although it induced damage to
astroglia. This resultis quiteintriguing andcouldbeinvolved
in the inﬂammation process in SN. These results point out
the important contribution of DA to the vulnerability and
degeneration of dopaminergic neurons of the SN. Further
knowledge about the involvement of DA in this process may
leadtothepossibility ofnewprotectionstrategies againstthis
important degenerative process.6 ISRN Neurology
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Figure 2: Interaction between glia and neurons may lead to neuron damage and death. LPS activates microglia from a resting state to an
activatedone,probablythroughtheCD14andtheTLR4receptors;thissignallingpathway,mediatedbydiﬀerentmolecularadaptors,kinases,
and MAP kinases, activates NF-κB with the consequent transcription of speciﬁc genes leading to microglial activation. Then, activated
microglialcells release severalcompounds, as proinﬂammatorycytokines, radicaloxygen species (ROS),andNO that mayeventually lead to
neuronal death. Within dopaminergic neurons, the mitochondrial respiratory chain can be aﬀected by several substances, leading to energy
failure, production of ROS, and reduction of the neurons viability. ROS can act as signal for the activation of microglia, indicating that
neurons are not healthy. DA can exert a toxic action through the ROS formed in its oxidative metabolism; it may also forms complexes with
cysteine, inhibiting the respiratory chain and producing more ROS. The reduction/elimination of microglial induction could ameliorate
neuronal damage.
7.Other Naturaland EndogenousCompounds
Ableto Induce theInﬂammatory
ProcessalongwiththeDegenerationof
Dopaminergic Neurons by
IntranigralInjection
LPS is a compound derived from de bacterial cell wall; thus,
itcouldbeconsideredanexogenoussubstancetothenervous
system;othernaturaland endogenouscompoundshavebeen
described to have similar properties on this process.
7.1.Histamine. Wehaveevaluatedtheeﬀectsofadirectinfu-
sion of histamine (HA) in SN, striatum, medial septum, and
medial lemniscus. There were many reasons for carrying out
these experiments. Histamine is an important component of
mastcellsofthebrainandparticipatesintheenhancementof
microvascular permeability, leukocyte rolling, adhesion, and
extravasations ofinﬂammatory cellsintothebrainandspinal
cord. These events are important in many inﬂammatory
diseases of the CNS, such as encephalomyelitis and multiple
sclerosis [90]. It is also released after trauma, ischemia,
seizures, and inﬂammation [91]. Moreover, the brain also
has histaminergic neurons located in the tuberomammillary
nucleus of the posterior hypothalamus nucleus that project
to almost all regions of the brain from the olfactory bulb
to the spinal cord [92]. This neuronal HA acts as neuro-
modulatororneurotransmitter [93, 94], participating also in
many physiological functions [93–95]. It also interacts with
some neurotransmitter as DA [96–101]. This relationship
could be involved in the interaction between central HA
neurons with the extrapyramidal system. It is known that
HAinduces catalepsy, which has been suggested as an animal
model of Parkinson’s disease [102]. HA antagonists are used
as antiparkinsonian drugs [103].
HAhas beenshown to be involvedinneuronal degenera-
tion [104] and neurotoxicity [105]. Wernicke’s encephalopa-
thyisadisordercharacterized byselectivepathologicdamage
to the midline thalamus, mammillary bodies, and certain
brainstem nuclei. Thiamine deﬁciency is a critical factor in
the etiology of this disorder. Langlais et al. [104]u s i n ga
rat model of Wernicke’s encephalopathy induced by an acute
bout of pyrithiamine-induced thiamine deﬁciency (PTD),
pointed out that HA mediated neuronal death in this model.ISRN Neurology 7
In our study [106], the injection of histamine in SN pro-
ducedanacuteinﬂammatory responsemanifestedbyanacti-
vationofmicroglia,whereOX-42-immunoreactivemicroglia
exhibited typical features of phagocytic cells. In addition, a
marked induction of MHC class II antigen expression and a
characteristic disappearance of the GFAP immunoreactivity
were produced in the same area. These eﬀects were accom-
panied by a selective damage in dopaminergic neurons, evi-
denced by the loss of tyrosine hydroxylase mRNA-expressing
cells, tyrosine hydroxylase-immunolabeled-positive cell bod-
ies, and a decrease of DA and 3,4-dihydroxyphenylacetic
acid levels. However, HA injection had little eﬀect in other
areas; only high doses produced an evident dopaminergic
terminal degeneration. Moreover, similarly to that described
for LPS, HA produced the speciﬁc degeneration of DA
neurons of SN; HA did not aﬀect GABAergic neurons, alter
the pattern of ChAT mRNA-expressing cells, or change the
pattern of 5-HT-immunolabeled cells when it was injected
in SN, septum, or the medial lemniscus, respectively. We
conclude that, similarly to LPS, HA is a selective neurotoxin
for dopaminergic cells.
HA eﬀect must be related to its inﬂammatory capability
along with the rapid and reversible increase in the BBB
permeability, producing a disturbance of the normal brain
homeostasis. Moreover, a direct neurotoxic eﬀect of HA over
the nigral dopaminergic population should never be dis-
carded, since there are reports on the induction of neuronal
death by HA [104, 105]. In spite of the strict and remarkable
selective neurotoxic action of HA on the dopaminergic
system, HA may be taken into account in relationship to
its involvement in the etiopathology of PD. So, higher
blood HA levels have been found in patients with PD than
in healthy controls [107]. However, central histaminergic
systems are not aﬀected in PD [108]. It has been shown that
mast cells can rapidly penetrate brain blood vessels from
extraneuronal sources [109]. It is interesting to note that
therapies used in PD (L-DOPA + carbidopa) decrease the
blood HA concentration [107], probably due to the decrease
in itsformation [110]. In addition, HA antagonistshave long
been used as antiparkinsonian drugs [103]. Patients with
idiopathicPDtreatedwithfamotidine, anHAH2antagonist,
demonstrated improvement in their motor symptoms [111].
In addition, some HA metabolites and derivatives have
been correlated with the degree of severity in PD patients.
Levels of pros-methylimidazolacetic acid in cerebrospinal
ﬂuid showed a high positive correlation with the severity
of PD in a group of not medicated, mildly to moderately
aﬀected patients [112, 113]. Further indications supporting
theinvolvementofHAintheetiopathologyofPDcomefrom
the observation that an increase in HA concentration was
associated withtheappearance orworsening ofparkinsonian
symptoms. Thus, acute tacrine administration produced
tremulous jaw movements that shared some characteristics
with parkinsonian tremor [114–116]. Tacrine is an inhibitor
of brain histamine N-methyltransferase, which increases
brain HA concentration [117]. Combined treatment with
tacrine and haloperidol increases the parkinsonian-like
symptoms [118, 119]. Secondary Parkinsonism has been
described in neurocysticercosis [120, 121], characterized by
ad i ﬀuse brain edema [122] generally accompanied by an
increase of HA levels.
In conclusion, we showed for the ﬁrst time that HA
was able to produce a speciﬁc degeneration of dopaminergic
neuronsinSNalongwithahighlyinﬂammatory process.The
dose of HA needed to produce this eﬀect was remarkably
lower than that described in other studies. Besides, many
of the relationships between elevated HA concentration and
parkinsonism-like symptoms were pointed out. All these
data strongly suggested an important relationship between
elevated concentrations of HA and degeneration of the
nigrostriatal dopaminergic system, which requires further
investigation.
7.2. Thrombin. Thrombin is a multifunctional serine pro-
tease, best known for its role in the blood coagulation cas-
cade. It is derived from its zymogen, prothrombin, and con-
verts ﬁbrinogen into ﬁbrin. It has many functions: activates
platelets, stimulating the proliferation of vascular smooth
muscle cells [123–125]; it is involved in the chemotaxis and
adhesion in monocytes, macrophages, and neutrophils (for
review, see Grand et al. [126]); it has speciﬁc eﬀects in cells
of the CNS, regulating neurite outgrowth in neuronal cells
[127] and inducing the proliferation of astrocytes [128];
it is also able to induce the activation and proliferation
of cultured rodent microglia along with the production
of nitric oxide (NO); it evokes the release of cytokines
and chemokines [129] and induces the proliferation of
astrocytes [128, 130]. The lattereﬀectscouldbe important in
relationship to inﬂammatory processes. It is also interesting
that brain contains this and some other proteases, along
with protease-activated receptors (PARs) that serve key roles
in blood coagulation and wound healing. These proteases
have actually been found in the brain in situations in
which the BBB is compromised, with a possible role in the
neuropathological triggering of this situation (for review,
see Gingrich and Traynelis [131]). Taking into account all
these properties, along with the possible eﬀect of thrombin
in stroke, we studied thrombin eﬀects on the nigrostriatal
dopaminergic system.
Following the experimental procedure carried out in our
previous works, we injected diﬀerent amounts of throm-
bin into the nigrostriatal pathway [132]. Seven days after
injection, we found a strong inﬂammatory response in the
SN with a strong macrophage/microglial reaction pointed
out by immunostaining (using OX-42 and OX-6 antibodies)
and the induction of iNOS, IL-1α,I l - 1 β,a n dT N F - α.T h e s e
results showed that the infusion of thrombin induced an
inﬂammatory process in a similar way to other proinﬂam-
matory compounds such as LPS, probably by the activation
of microglial cells, as described for microglial cultures [129].
The thrombin-induced inﬂammation was produced by its
biological activity, maybe through the protease-activated
receptors- (PAR-) receptor, since the injection of heat
denatured thrombin or thrombin plus α-NAPAP (a speciﬁc
inhibitor of thrombin) did not induce these processes, or
they were strongly reduced. Moreover, selective damage
to dopaminergic neurons was produced after thrombin8 ISRN Neurology
injection, evidenced by loss of TH immunostaining and
TH mRNA expressing cell bodies, and the unaltered tran-
scription of glutamic acid decarboxylase (GAD) mRNA in
the SN and striatum. These eﬀects were also produced
by its biological activity since they almost disappeared when
thrombin was heat-inactivated or injected with its inhibitor
α-NAPAP.
These thrombin eﬀects were even more interesting if
we remember that thrombin is activated from prothrombin
in the coagulation cascade and also that it enters inter-
stitial ﬂuid during penetrating head wounds, hemorrhagic
stroke, rupture of cerebral aneurysms, and arteriovenous
malformations. In addition, BBB breakdown associated
with cerebrovascular insults reﬂects a largely nonselective
increase in the permeability of brain capillaries and tight
junctions to high molecular weight proteins. Moreover,
taking into account that prothrombin circulates in blood at
high concentrations (1 μM) [133]a n dv a s c u l a ri n j u r y
triggers its rapid conversion to thrombin, direct entry of
thrombin into the interstitial space with the consequence of
a signiﬁcant increase in its concentration is plausible [134].
Moreover, the elevation of thrombin levels in cerebrospinal
ﬂuid from 100pM to 25nM for a period of more than
a week has been reported in subdural hematoma [135].
This suggests that appreciable amounts of thrombin can
be generated and persist at sites of cerebrovascular injury.
When bleeding occurs directly within brain tissue, active
thrombin, and other proteases will freely penetrate the
interneuronal spaces by diﬀusion until clotting closes the
injured vessels and thrombin becomes depleted from the
clot. High concentrations of thrombin, such as those that
can be produced by a cerebral hemorrhage, appear to
cause brain damage [133, 136] and may also contribute to
damage in Alzheimer’s disease and vascular dementia [137–
139]. Vascular Parkinsonism has also been reported [140];
moreover, features of Parkinsonism have been seen in up to
38% of lacunar stroke patients at one year [141].
All these data provided evidence that thrombin activates
microglia along with other inﬂammatory features in the SN,
resulting in speciﬁc degeneration of dopaminergic neurons.
These results suggest that thrombin, as an endogenous
neurotoxin, could be implicated in dopaminergic neuron
degeneration.BesidesPD,thesefeaturescouldalsobeofrele-
vance fora wide range ofneurologicaldiseases which present
pathological signs of inﬂammation, such as cerebrovascular
diseases and CNS trauma.
Similar results were described by Choi et al. [142]. It
is interesting to note that the inﬂammatory process and
the degenerative induction produced by intranigral injection
of thrombin are not overcome by the treatment with
dexamethasone as anti-inﬂammatory agent [143]. In fact,
when we studied the possible protection exerted by dexam-
ethasone in the thrombin paradigm, we found unexpected
results. Dexamethasone was able to prevent partially the
l o s so fa s t r o c y t e sb u tw a su n a b l et oo v e r c o m eo t h e ri n ﬂ a m -
matory features, as the microglial proliferation induced by
thrombin. Moreover, this treatment resulted in a greater
loss of dopaminergic neurons that was accompanied by
the accumulation of α-synuclein in dopaminergic neurons,
probably produced by the diminution of its degradation, an
eﬀect described to be produced by dexamethasone on the
beta-amyloid [144]. Dexamethasone produced other eﬀects,
as the consequent aggravation of the ischemic neuronal
damage in striatum [145] and hippocampal CA1 area [146]
as the extracellular accumulation of glutamate increased and
thereby the overload of cellular calcium [147].
We also found that dexamethasone produced a signiﬁ-
cant decrease in PAR-1, which was increased by thrombin
plus dexamethasone; nexin-1, the most abundant, potent
endogenous thrombin inhibitor in brain [148], was not
also aﬀected by dexamethasone alone but was increased by
thrombin; the eﬀect was greater and in the same direction
when thrombin and dexamethasone were used together.
Dexamethasone produced a greater amount of oxidative
stress (measured as carbonyl groups) than thrombin, in a
similar extension that in animals treated with thrombin plus
dexamethasone. We suggest that this increase of oxidative
stress could be the cause of the great damage produced
by dexamethasone. The cause of the oxidative stress is
the increase of DA metabolism produced by the release
of DA along with its metabolism through MAO enzymes.
It is known that MAO-A is induced by glucocorticoids
in tissues as human skeletal muscle [149]o rb o v i n e
adrenal endothelial cells [150]. Dexamethasone increased
the expression of MAO-B in rat astrocytes, which was
inhibited by the glucocorticoids receptor inhibitor RU486
[151]. Moreover, the relationship between MAO-dependent
H2O2 overproduction and degenerative processes had been
suggested in PD [152]. These data suggested that H2O2
producedby MAO played an important role in the induction
of apoptosis under some conditions. In our experimental
design, both MAO A and B increased in animals treated with
dexamethasone. Moreover, when we blocked MAO activity
with tranylcypromine, the death of dopaminergic neurons
caused by the combined treatment with thrombin and
dexamethasone was prevented. This supports that induction
o fM A Oa c t i v i t yb yd e x a m e t h a s o n em i g h tp l a ya ni m p o r t a n t
role in the lack of protection against thrombin observed
in the animals treated with this glucocorticoid. This result
is also in agreement with Tazik et al. [153], who recently
described the protective eﬀect of rasagiline, an inhibitor
of MAO B, on dexamethasone-induced brain apoptosis.
Increase of DA metabolism produced by dexamethasone
through the induction of MAOs could be important in
dopaminergic neurons, since DA seems to play an active role
in their degeneration [154].
7.3. Tissue Plasminogen Activator (tPA). tPA is a highly spe-
ciﬁc serine proteinase and one of the two principal plas-
minogen activators. It is widely distributed in all brain
regions across the neuroaxis, being more elevated in the
spinal cord and the SN [155, 156]. Diﬀerent functions
have been suggested for tPA in the CNS; for our work,
the most important was the neurotoxicity eﬀect [157–162].
Diﬀerent animal models had demonstrated that the genetic
deﬁciency of tPA [159, 163] and its inhibition with the
natural tPA inhibitor neuroserpin [164, 165] were associatedISRN Neurology 9
with a decrease in infarct volume and signiﬁcant neuronal
survival comparedwith control animals. Moreover,tPA plays
important rolesin bloodcoagulation and ﬁbrinolysisoutside
the CNS. By cleaving the precursor molecule plasminogen,
plasminogen activators produce the active enzyme plasmin,
which dissolves ﬁbrin-based clots in focal cerebral ischemia.
Clinical trials have demonstrated that treatment with plas-
minogenactivators inselectedpatientscanimproveoutcome
after acute ischemic stroke [166]. Moreover, tPA is the only
drug approved for the treatment of thromboembolic stroke,
but it might lead to some neurotoxic side eﬀects. Some
of these eﬀects could be related with the fact that tPA,
as thrombin, is able to induce microglia [167], probably
with the consequent activation of an inﬂammatory process
that could be responsible for some of the neurotoxic eﬀects
reported after its pharmacological use.
We have used the intranigral injection of tPA, which
let us to describe its eﬀects under standardized conditions.
We found that injection in the SN led to the induction of
inﬂammatory process, microglial activation, loss ofastroglia,
and increase in the expression of nNOS, iNOS, and aqua-
porin 4, along with the disruption of the BBB integrity. This
latter result is in agreement with Yepes et al. [168]a n dG o t o
et al. [169] which showed that recombinant tPA promotes
acute direct neurotoxicity with disruption of the BBB and
increased formation of edema. Moreover, we also found
a dose-dependent loss of dopaminergic neurons, pointed
out by TH-immunoreactivity and changes in the expression
of TH and DAT mRNAs. The toxic eﬀect of tPA seemed
to be speciﬁc on dopaminergic neurons of the SN since
the GABAergic population of the ventral midbrain was not
aﬀected.
These results could be related to—and could also
justify—the possible neurotoxic eﬀect produced by tPA in
those pathological conditions which result in a signiﬁcant
increase of its production and release. It is known that
endogenous tPA activity increases signiﬁcantly by ischemia
[159]; this eﬀect is prevented in animals with genetic
deﬁciency of tPA [159, 163] and also by the treatment with
the natural tPA-inhibitor neuroserpin [164, 165]. Ischemia
should be produced early in the SN to observe the degenera-
tion of dopaminergic neurons induced for tPA. However, we
must note thatwe carried outotherexperiments in which we
injected tPA intravenously at nearly clinical concentration,
along with the injection of saline solution in the SN in order
todisrupttheBBB;we didnotﬁndasigniﬁcant degeneration
of the dopaminergic system, suggesting that the damage
observedinourmodel should be producedby theincrease in
the endogenous concentration of tPA and its extravasations
by isquemia.
7.4. Trisialoganglioside. The intranigral injection of Trisialo-
ganglioside GT1b, one of the major brain gangliosides,
induced a great inﬂammatory response along with the
degeneration of dopaminergic neurons [170]. This is also
relevant since gangliosides, a component of membranes, are
also involved in some neurodegenerative processes in which
they accumulate. The ability of these compounds to induce
inﬂammation could be important.
8.PeripheralInﬂammationEnhancedthe
InﬂammationProducedby the Intranigral
InjectionofLPSand,Consequently,the
Degenerationof Dopaminergic Neurons
As we have described above, evidence suggesting that
inﬂammation may play a central role in the cell loss seen in
PD has been accumulating during years (see [14]; for review
see [15, 16]). Moreover, some relationship between central
inﬂammation and peripheral could be possible. It is known
that the chance of developing AD is increased twice in aged
persons exposed to systemic infections [171]. Furthermore,
Strang [172] described the increased prevalence of peptic
ulcer prodromal to idiopathic Parkinsonism [173]. Thus,
we were interested in using our animal model of PD to
study the implication of peripheral inﬂammation [174].
To achieve peripheral inﬂammation, we used a model of
ulcerative colitis (UC) induced by dextran sulphate sodium
(DSS) ingestion [175] .W ed e s c r i b e da ni n c r e a s ei nt h el e v e l s
of inﬂammatory markers from serum (TNF-α,I L - 1 β,I L - 6 ,
and the acute phase protein C-reactive protein). Moreover,
it also increased the inﬂammatory parameters in SN (TNF-
α,I L - 1 β, IL-6, iNOS, intercellular adhesion molecule-1
(ICAM-1),and microglialand astroglial populations)caused
by the intranigral injection of vehicle in animals with
UC. Consequently, peripheral inﬂammation induced by
UC increased all the LPS-induced inﬂammatory markers
examined in the ventral mesencephalon, demonstrating
that SN becomes more sensitive to central inﬂammatory
stimulus under conditions of peripheral inﬂammation. The
inﬂammatory response of SN was associated to increased
vulnerability of its dopaminergic population. These results
suggest that inﬂammation produced in a peripheral organ
(intestine) could induce loss of dopaminergic neurons in
the SN, enhancing the inﬂammation and the dopaminergic
degeneration induced in the SN by a previous inﬂammation
(LPS). Moreover, we also studied the possibility that leuko-
cyte inﬁltration through an impaired BBB could be involved
in the deleterious eﬀects of systemic inﬂammation on nigral
dopaminergic population under conditions of brain inﬂam-
mation. Brochard et al. [176]h a ds h o w nl y m p h o c yt eTi n ﬁ l -
tration into brain parenchyma in MPTP-intoxicated mice
showing induction of ICAM-1 but no BBB disruption. Our
analysis demonstrated that UC inducedICAM-1 levelsin the
ventral mesencephalon; ﬂow cytometry analyses showed that
the amount of circulating monocytes was higher in animals
from the LPS and UC groups (around fourfold) than in
the control animals. Inﬁltration in the UC + LPS group
increased nearly eightfold. Moreover, using the intravenous
injection ofclodronateencapsulatedin liposomes(ClodLip),
which produced a peripheral macrophage depletion lasting
5 days in blood, liver and spleen of normal rats and
mice [177–179], we found the reversion of the deleterious
eﬀect of peripheral inﬂammation on microglial activation,
BBB disruption, astrocytes loss, and degeneration of nigral10 ISRN Neurology
dopaminergic neurons induced by LPS. Taken together, our
results demonstrate that peripheral inﬂammation induced
by UCcontributesto dopaminergic degeneration.Activation
of macrophages seems a decisive factor, since destruction
of this peripheral leukocyte type by ClodLip abolishes the
nocive eﬀects on the ventral mesencephalon associated with
UC. This study shows that BBB disruption may increase
brain susceptibility to subsequent exposure to circulating
leukocytes. This study may also shed light into previous
observations;itdescribedtheexistenceofanincreasedpreva-
lence of peptic ulcer prodromal to idiopathic Parkinsonism
[172, 180]. This has prompted some authors to suggest a
prominent role of inﬂammation in gastrointestinal tract in
the etiology and pathogenesis of idiopathic Parkinsonism,
including a possible role for Helicobacter pylori infections
[173, 181]. This infective process is the most prevalent in the
world, aﬀecting approximately 50% of the population [182],
a n di ti sc o n s i d e r e dt h ec a u s a t i v ea g e n to fm a n yg a s t r o i n -
testinalandextradigestiveconditions.Colonizationofgastric
mucosa by H. pylori is accompanied by an inﬂammatory
response associated with gastric mucosal damage through
the activation of polymorphonuclear neutrophil leukocytes
[183],inﬂammatory inﬁltration oflymphocytes,plasma cells
and macrophages in the stomach tissue [184–186], and the
production of pro-inﬂammatory factors such as IL-8, IL-1,
and TNF-α [187–189].
9.Conclusions
On 1998, we proposed an animal model of PD based on the
inﬂammatory process triggered by the intranigral injection
of LPS. Afterwards, this model was further developed and
corroborated that the SN had the highest response to
inﬂammation process induced by LPS with respect to other
brain areas studied. In addition, one of the responses to
inﬂammation was the speciﬁc degeneration of dopaminergic
neurons. The implication of inﬂammation in the degener-
ation of dopaminergic neurons was also supported by the
protection produced by many diﬀerent anti-inﬂammatory
compounds. The interest of this model is to point out the
fact that inﬂammation is the inductor of the degeneration of
dopaminergic neurons, probably in cases as injury, boxing,
infection, and others; it could be important in the progres-
sion of the disease at the same time that it could enhance
t h ed a m a g ei n d u c e db yt h em a i n( u n k n o w n )c a u s eo ft h e
disease. Moreover, the interest ofthe scientiﬁc community in
inﬂammation in PD has increased signiﬁcantly afterwards.
In all cases, the anti-inﬂammatory pharmacology could be
important in the disease, and this model could be also
very useful to test anti-inﬂammatory treatments. Moreover,
the model has allowed pointing out that any endogenous
substance able to induced inﬂammation or activation of
microglia produced similar eﬀectsto LPS. Many endogenous
compounds have been used in this way, as histamine,
thrombin, or tPA among others. Some of them could have
ad i r e c te ﬀect in this disease, as stroke or infection. With
respect to the special sensitivity of the SN to inﬂammation,
there are no clear answers, but its knowledge would be of
interest for the treatment of PD. The special sensitivity of
dopaminergic neurons to inﬂammation is also of special
interest; in this case, however, the increase of free radicals
productionthroughMAOenzymesandtheeﬀectofDAseem
clear. Our model make possible to study other processes, as
peripheral inﬂammation, which could enhance the eﬀects
produced by central inﬂammation.
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